268 related articles for article (PubMed ID: 33279413)
1. Modified Glasgow Prognostic Score as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated With Nivolumab.
Fujiwara R; Takemura K; Fujiwara M; Yuasa T; Yasuoka S; Komai Y; Numao N; Yamamoto S; Yonese J
Clin Genitourin Cancer; 2021 Apr; 19(2):e78-e83. PubMed ID: 33279413
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
[TBL] [Abstract][Full Text] [Related]
3. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
4. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
5. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab after Failure of Prior Tyrosine Kinase Inhibitors.
Takemura K; Yuasa T; Fujiwara R; Ito M; Suzuki H; Yonese J; Koga F
J Urol; 2020 Dec; 204(6):1166-1172. PubMed ID: 32567459
[TBL] [Abstract][Full Text] [Related]
7. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
8. Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab.
Ueda K; Suekane S; Kurose H; Ogasawara N; Hiroshige T; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
Jpn J Clin Oncol; 2022 Feb; 52(2):179-186. PubMed ID: 34607361
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab.
Ekinci F; Erdogan AP; Yildirim S; Bulut G; Yilmaz C; Barutca S
J Coll Physicians Surg Pak; 2022 Oct; 32(10):1288-1294. PubMed ID: 36205273
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment.
Ishihara H; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
Target Oncol; 2016 Oct; 11(5):605-617. PubMed ID: 27023922
[TBL] [Abstract][Full Text] [Related]
12. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
Matsuki T; Okamoto I; Fushimi C; Sawabe M; Kawakita D; Sato H; Tsukahara K; Kondo T; Okada T; Tada Y; Miura K; Omura G; Yamashita T
Cancer Med; 2020 Jul; 9(14):5015-5024. PubMed ID: 32441463
[TBL] [Abstract][Full Text] [Related]
13. Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy.
Tsujino T; Komura K; Matsunaga T; Yoshikawa Y; Takai T; Uchimoto T; Saito K; Tanda N; Oide R; Minami K; Uehara H; Jeong SH; Taniguchi K; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
Ann Surg Oncol; 2017 Sep; 24(9):2787-2793. PubMed ID: 28643013
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma.
Cho DS; Kim SI; Choo SH; Jang SH; Ahn HS; Kim SJ
Scand J Urol; 2016 Jun; 50(3):186-91. PubMed ID: 26878156
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.
Lamb GW; Aitchison M; Ramsey S; Housley SL; McMillan DC
Br J Cancer; 2012 Jan; 106(2):279-83. PubMed ID: 22166802
[TBL] [Abstract][Full Text] [Related]
18. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
[TBL] [Abstract][Full Text] [Related]
19. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.
Herrmann T; Ginzac A; Molnar I; Bailly S; Durando X; Mahammedi H
Cancer Med; 2021 Oct; 10(19):6705-6713. PubMed ID: 34405573
[TBL] [Abstract][Full Text] [Related]
20. Predictive role of γ-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma.
Ishiyama Y; Kondo T; Tachibana H; Ishihara H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Tanabe K
Int J Clin Oncol; 2021 Mar; 26(3):552-561. PubMed ID: 33135126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
